Sources

5 Total Sources

Abivax Shares Sink 32% Despite 51% Remission in Phase 3 Colitis Trial

Left50%
Center25%
Right25%
STAT14h ago
Abivax Shares Tank on Cancer Concerns Despite Obefazimod's Strong Phase 3 Ulcerative Colitis Efficacy
The Wall Street Journal14h ago
Abivax Shares Plunge After Company Reports Adverse Events in Key Drug Trial - WSJ
CNBC14h ago
Abivax Shares Plunge 32% After Ulcerative Colitis Drug Trial Shows Cancer Cases
Yahoo Finance14h ago
Abivax stock sinks 32% as rare malignancy events cloud solid colitis trial data
intellectia.ai14h ago
Abivax Shares Plunge 32% Amid Cancer Risk Concerns | Intellectia.AI